Novo partners with Orbis, deepening investment in oral peptide drugs

The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.

By Jonathan Gardner • Sept. 17, 2026

Roche, Dualitas team up to find bispecific drugs for immune diseases

Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments. 

By Gwendolyn Wu • Sept. 17, 2026

Explore the Trendline➔

Alzheimer's disease

Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

By BioPharma Dive staff

Novartis to pay $125M for blood-brain barrier crossing platform

Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential.

By Delilah Alvarado • Sept. 16, 2026

Novo looks to Anthropic’s AI models to ‘supercharge’ drug development

The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company."

By Kristin Jensen • Sept. 16, 2026

AstraZeneca’s newly approved pill fails frontline breast cancer study

Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year. 

By Delilah Alvarado • Sept. 14, 2026

Andy Plump, architect of Takeda’s R&D overhaul, to retire next year

Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it with what CEO Julie Kim called a “lasting foundation.”

By Kristin Jensen • Sept. 10, 2026

Novartis RNA drug falls short in rare muscle disease study

The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.

By Jacob Bell • Sept. 8, 2026

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

By Jonathan Gardner • Sept. 4, 2026

This week in charts: China deals, stock flatlines and Lilly’s M&A spree

Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.

By Gwendolyn Wu • Sept. 4, 2026

GSK wagers up to $1.3B on a different kind of cancer drug

With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.

By Delilah Alvarado • Sept. 3, 2026

Akeso, Summit cancer drug confirms lung cancer survival benefit

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.

By Jonathan Gardner • Sept. 3, 2026

Mid-cap biotechs join Trump’s latest round of drug pricing deals

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.

By Jonathan Gardner • Sept. 1, 2026

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.

By Jonathan Gardner • Aug. 28, 2026

This week in charts: Biotech’s rebound is undeniable

Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

By Jacob Bell • Aug. 28, 2026

New data could widen use of AstraZeneca, Amgen immune disease drug

Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.

By Delilah Alvarado • Aug. 27, 2026

Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test

Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.

By Susan Kelly • Aug. 25, 2026

Roche commits to lean-mass preservation with Hanmi obesity deal

For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.

By Jonathan Gardner • Aug. 24, 2026

[Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

By BioPharma Dive's studioID • Aug. 24, 2026

Pharma marketers need a share-of-answer strategy before AI spend

AI is changing how HCPs seek answers. Pharma marketers need a new strategy.

Aug. 24, 2026

Shareholder pressures Capricor; Lilly dives deeper into vaccines

Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery engine.

By BioPharma Dive staff • Aug. 21, 2026

How cost and perception could reshape the GLP-1 market

As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.

By Kelly Bilodeau • Aug. 21, 2026

AstraZeneca scores in lung cancer; Sandoz inks a China deal

A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.

By BioPharma Dive staff • Aug. 18, 2026

AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer

An interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.

By Jonathan Gardner • Aug. 17, 2026

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

By Jonathan Gardner • Aug. 14, 2026

Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide

Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.

By Kristin Jensen • Aug. 12, 2026